Table 3. P1 blood culture episodes where FA-BCID test results enabled a treatment modification.

	FA-BCID test result	Routine ID result	Treatment switch initiated by FA-BCID test result
			type	antibiotic	TAT OAT
1	mecA-neg S. aureus	S. aureus	de-escalation	flucloxacillin	01:10
2	S. pneumoniae	S. pneumoniae	initiation	penicillin	01:44
3	blaKPC-neg E. cloacae complex	E. cloacae complex	broadening	ciprofloxacin	01:53
4	mecA-neg S. aureus	S. aureus	initiation	flucloxacillin	02:07
5	mecA-pos S. haemolyticus	S. haemolyticus	initiation	vancomycin	02:23
6	vanA/B-neg Enterococcus	E. faecalis	initiation	ampicillin	02:26
7	blaKPC-neg S. marcescens	S. marcescens	initiation	temocillin	02:34
8	S. pneumoniae	S. pneumoniae	initiation	penicillin	02:46
9	mecA-neg S. aureus	S. aureus	initiation	flucloxacillin	03:03
10	mecA-neg S. aureus	S. aureus	initiation	flucloxacillin	03:37
11	blaKPC-neg E. coli	E. coli	initiation	cefuroxime	03:42
12	mecA-pos S. aureus	S. aureus	broadening	vancomycin	03:47
13	C. albicans	C. albicans	initiation	fluconazole	03:50
14	mecA-pos S. aureus	S. aureus	initiation	vancomycin	03:57
15	Streptococcus	S. milleri group	de-escalation	ampicillin	04:25
16	S. thermophilus	S. viridans	initiation	ampicillin	04:33
17	mecA-neg S. aureus	S. aureus	de-escalation	flucloxacillin	05:27
18	mecA-neg S. aureus	S. aureus	de-escalation	flucloxacillin	06:33
19	mecA-neg S. aureus	S. aureus	initiation	flucloxacillin	06:40
20	blaKPC-neg P. aeruginosa	P. aeruginosa	broadening	ceftazidime	06:50
21	mecA-neg S. aureus	S. aureus	initiation	flucloxacillin	07:13
22	C. glabrata	C. glabrata	broadening	anidulafungin	08:00
23	mecA-neg S. aureus	S. aureus	de-escalation	flucloxacillin	11:04
24	blaKPC-neg E. coli	E. coli	de-escalation	cefuroxime	11:40
25	blaKPC-neg S. marcescens	S. marcescens	initiation	piperacillin + tazobactam	13:29
26	L. monocytogenes	L. monocytogenes	de-escalation	ampicillin	15:52
27	C. glabrata + mecA-neg S. aureus	C. glabrata	initiation	anidulafungin + flucloxacillin	15:53
28	blaKPC-neg E. cloacae complex	E. cloacae complex	initiation	temocillin	26:17
29	blaKPC-neg E. coli	E. coli	initiation	ceftriaxone	30:30
30	blaKPC-neg E. coli	E. coli	initiation	cefuroxime	33:55
31	blaKPC-neg E. coli + vanA/B-neg Enterococcus	E. coli + E. faecalis	initiation	cefuroxime + vancoymcin	34:33
32	blaKPC-neg E. coli	E. coli + C. perfringens	initiation	cefuroxime	37:30
33	mecA-neg Staphylococcus + vanA/B-neg Enterococcus	S. epidermidis + E. faecalis	broadening	vancomycin	40:12
34	blaKPC-neg P. aeruginosa	P. aeruginosa	broadening	ceftazidime	65:30
35	blaKPC-neg A. baumannii + mecA-neg Staphylococcus	A. baumannii + S. haemolyticus	broadening	meropenem	108:48

In episode 1–26, the modified treatment upon FA-BCID result was the OAT. In episode 27–35, further tailoring was necessary following ID and AST results. The TAT to OAT is reported in hours:minutes.

Abbreviations: AST, antimicrobial susceptibility testing; FA-BCID, FilmArray blood culture identification; ID, identification; OAT, optimal antimicrobial treatment; TAT, turn-around-time; P1, intervention period.